Stock Price Movements and Program Launches Reported by Healthcare Companies - Research Report on Merck, Abiomed, Alere, Raptor Pharmaceuticals and West Pharmaceutical Services Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 26, 2013 NEW YORK, November 26, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Abiomed Inc. (NASDAQ: ABMD), Alere Inc. (NYSE: ALR), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), and West Pharmaceutical Services, Inc. (NYSE: WST). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Merck & Co. Inc. Research Report On November 19, 2013, Merck & Co. Inc. (Merck) announced that its initiative, Merck for Mothers, has launched programs which are aimed at reducing the number of women across the US who die from and suffer severe complications related to pregnancy and childbirth. The Company stated that Merck for Mothers, which is already working in over 20 countries including Brazil, India, Senegal, Uganda and Zambia, is now working in the US to address the following areas: to enhance community initiatives so mothers have access to services that encourage good health during and beyond pregnancy; to implement standard approaches addressing obstetric emergencies; and to strengthen data collection and reviews to improve practices and patient care. Kenneth C. Frazier, Chairman and CEO of Merck stated, "The rate of maternal mortality is increasing here in the United States. The tragedy is that many of these deaths are actually preventable. Merck is working with partners around the globe to help improve the situation everywhere, including in the United States, to create a world where no woman dies while giving life." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/430d_MRK -- Abiomed Inc. Research Report On November 21, 2013, Abiomed Inc.'s (Abiomed) stock closed at $28.37, reflecting a 4.03% increase. The Company' stock was up by 5.11% over the past three trading days, compared to the Dow Jones Industrial Average which went up by 0.21% during the same trading period. The Full Research Report on Abiomed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/ea34_ABMD -- Alere Inc. Research Report On November 21, 2013, Alere Inc.'s (Alere) stock went up by 0.80% closing at $32.89 per share. The Company's stock was down 1.26% over the previous three trading sessions, compared to the S&P 500, which was up by 0.24% during the same trading period. The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5da1_ALR -- Raptor Pharmaceuticals Corp. Research Report On November 21, 2013, Raptor Pharmaceuticals Corp.'s (Raptor Pharmaceuticals) stock was up by 7.83%, closing at $13.22. Over the past three trading sessions, the Company's stock was up by 9.98%, compared to the Nasdaq Composite, which went up by 0.51% during the same trading period. The Full Research Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/a001_RPTP -- West Pharmaceutical Services, Inc. Research Report On November 21, 2013, West Pharmaceutical Services, Inc.'s (West Pharmaceutical Services) stock was up by 3.13% closing the day at $48.80. The Company's stock went up by 3.11% over the past three trading sessions, compared to the Dow Jones Industrial Average, which went up by 0.21% during the same trading period. The Full Research Report on West Pharmaceutical Services, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/39a2_WST ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Stock Price Movements and Program Launches Reported by Healthcare Companies - Research Report on Merck, Abiomed, Alere, Raptor
Press spacebar to pause and continue. Press esc to stop.